chrisvoncsefalvay/vaers-outcomes huggingface dataset:
problem with breathing; very itchy eyes; hives increased at inner thigh, under arms; break out rash and hives/hives increased at inner thigh, under arms; edema around his eyes/very itchy eyes; This spontaneous case was reported by a dentist (subsequently medically confirmed) and describes the occurrence of URTICARIA (break out rash and hives/hives increased at inner thigh, under arms), OEDEMA (edema around his eyes/very itchy eyes), DYSPNOEA (problem with breathing), EYE PRURITUS (very itchy eyes) and URTICARIA (hives increased at inner thigh, under arms) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Cellulitis. Concurrent medical conditions included Drug allergy (Clarithromycin).    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 20-Jan-2021, the patient experienced URTICARIA (break out rash and hives/hives increased at inner thigh, under arms), OEDEMA (edema around his eyes/very itchy eyes), EYE PRURITUS (very itchy eyes) and URTICARIA (hives increased at inner thigh, under arms). On 22-Jan-2021, the patient experienced DYSPNOEA (problem with breathing). The patient was treated with PREDNISONE at an unspecified dose and frequency and CETIRIZINE HYDROCHLORIDE (ZYRTEC) at an unspecified dose and frequency. On 26-Jan-2021, URTICARIA (break out rash and hives/hives increased at inner thigh, under arms), OEDEMA (edema around his eyes/very itchy eyes) and DYSPNOEA (problem with breathing) had resolved and EYE PRURITUS (very itchy eyes) and URTICARIA (hives increased at inner thigh, under arms) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient took dalvance as infusion 3 years ago and is using pacemaker at high risk of COVID 19.
No known adverse effects; 18 years old patient received a dose of proquad and a dose of vaqta for adults; 18 years old received a dose of proquad; This spontaneous report was received from a medical assistant referring to a 18-year-old patient of unknown gender. Information regarding the patient's concurrent condition, pertinent medical history, drug reactions/allergies and concomitant medications were not provided. On 11-DEC-2019, the patient was vaccinated with a dose of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (product administered to patient of inappropriate age group) 1 dosage form (DF) lot # S025736 was an invalid lot for Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live and expiration date reported as 13-MAY-2022 and a dose of Hepatitis A Vaccine, Inactivated (VAQTA) 1 DF lot # S012250 expiration date reported as 07-JUL-2020 (incorrect dose administered) via unknown route for prophylaxis. Other suspect therapy included sterile diluent (lot/batch # and expiry date were not reported). No known adverse effects reported.
Patient states he has had a "migraine" since he received the vaccines. He said the pain started about an hour after he received the vaccine and has had no relief even with taking ibuprofen. He says the pain is mostly in his neck and the base of his skull.
stomach crmaps, vomiting, fever, cold chills, slept all day 16JUL93; began 24 hrs p/vax recvd; lasted 48 hrs;
Vaccine was expired on 24-Oct-2021 and was administered to patient on 25-Oct-2021; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was expired on 24-Oct-2021 and was administered to patient on 25-Oct-2021) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was expired on 24-Oct-2021 and was administered to patient on 25-Oct-2021). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine was expired on 24-Oct-2021 and was administered to patient on 25-Oct-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant product use was reported. Date the vial was initially stored in the refrigerator was unknown. Expiration date was reported as 24-Oct-2021. The vial did not undergo any temperature excursions. No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2022: Follow up received reporter address updated.
Extreme pain in joint. Cannot use arm to take off clothing. Diagnosed 08/04/2015 and rotator cuff tendonitis.
One day after my second vaccine I began to have burning, pain and pressure in my pelvic and back area. My urine color turned black/purple color.The color lasted for about six days and I am still having pelvic pain.
Vaccine was painful upon injection, my left arm hurt for 5 days and Tylenol did not relieve the pain. I felt very sick the day after the vaccine: tired, chills, night sweats, muscle aches and my heart rate was 124 bpm per my watch device.  My heart rate did return to normal, but it took about 2 hours.
This spontaneous report was received from a registered pharmacist concerning an approximately 72 year old female patient with no drug reactions or allergies. On 18-JAN-2013, the patient was vaccinated with 0.65 milliliter (ml) of ZOSTAVAX (lot number H01809 and expiry date: January 2014), subcutaneously in the left deltoid. No concomitant medications were reported. Approximately on an unknown date in 2013, after the vaccination, the patient experienced redness at the injection site which was described as being 8 centimeter (cm) in diameter. The patient was then admitted to unspecified hospital with pneumonia and developed arm and shoulder pain in left arm and left shoulder. Approximately on an unknown date in 2013, X-rays were performed in the hospital, but showed nothing. Approximately on an unknown date in 2013, the patient was discharged. After discharge, the patient experienced inability to lift arm and limited arm mobility, for which she was taking physical therapy for, but discontinued due to lack of pain and function improvement and financial concerns. She continued to have congestion, could not keep throat clear and that she could not sing anymore. The symptoms were unchanged 6 months after the injection. The patient sought medical attention (seeing physician monthly), but treatment information was not available. The relatedness for the events was unknown for ZOSTAVAX. Additional information has been requested.
Rash on forehead and private region; Fever radiating from rash; Rash is sensitive to pressure; Loss of sleep due to discomfort; Fever; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash on forehead and private region), PYREXIA (Fever radiating from rash), RASH (Rash is sensitive to pressure), INSOMNIA (Loss of sleep due to discomfort) and PYREXIA (Fever) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, the patient experienced PYREXIA (Fever). On 06-Apr-2021, the patient experienced RASH (Rash on forehead and private region), PYREXIA (Fever radiating from rash), RASH (Rash is sensitive to pressure) and INSOMNIA (Loss of sleep due to discomfort). On 01-Apr-2021, PYREXIA (Fever) had resolved. At the time of the report, RASH (Rash on forehead and private region), PYREXIA (Fever radiating from rash), RASH (Rash is sensitive to pressure) and INSOMNIA (Loss of sleep due to discomfort) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Pt. recv'd shot at 11am by 9pm muscle/ joint ache, sore arm. After 1 hour of sleep woke to red swollen arm. Bedridden for 1 day. Arm was swollen & hurt for 1 week.
Patient fully vaccinated with Moderna (patient reports received 2nd dose 1/2021) contracts COVID, requiring admission to the hospital on 8/1/2021 (symptoms began 7/28). Chief complaint included weakness, headache, urinary symptoms, malaise. Required 2-3L O2 (no baseline oxygen requirements) - reported on hospital day 3.   Patient treated with dexamethasone 4 mg.  Required at least 4 days of hospitalization (reported hospital day 3).
I have had three adverse events from the second COVID vaccine. 1- After the first vaccination I experienced an exacerbation of my Complex Regional Pain Syndrome (reported previously). It subsided in the interim between shots. After my second shot I have another exacerbation of my Complex Regional Pain Syndrome with burning at sites where I have had CRPS in the past.  2- Left arm from shoulder to elbow swollen shortly after the time of 2nd vaccination.  It has remained swollen 3 weeks after vaccination.  Last Thursday April 1st  I received my maintenance dose of my allergy shot one in my left arm and one in my right arm.  At the time of the shot I experienced excessive pain in my entire left arm  different than with prior shots. My left arm swelled up even more.  It is now 2" larger than my right arm.  There is still pain and swelling  in the left arm but range of motion is intact.  Saw the allergist today.  Only thing to do is to take an NSAID at this point.    3- joints in my left hand fingers are swollen.  They were not swollen prior to the second vaccination.  Rings on my left hand ring finger that were loose prior to 2nd vaccination are now tight.
102 fever, headache and chills--had to call out sick to work but resolved by the next day 2/3.
04/13  | 19:00  - Body aches begin - no pain around injection site 04/14 | 04:00 - Arm is slightly swollen and red, body aches intensify and extreme fatigue - slept remainder of the day.  I took Tylenol 04/15 | 04:00 - Arm is very swollen and hot, mild body aches and extreme fatigue - slept the remainder of the day. I took Tylenol 04/16 | 04:00 - Arm still swollen and hot, no body aches, somewhat fatigued and a nosebleed lasting about 45 minutes 04/16 | 15:30 - Another nosebleed lasting about 30 minutes  04/16 | 18:30 - Slow throbbing headache begins (no Tylenol) 04/17 | 04:00 - Arm swelling is reduced, no body aches, minor fatigue, minor headache remains (no Tylenol) 04/17 | 11:15 - Another nosebleed lasting about 45 minutes.  I just kind of laid around not doing much 04/18 | 04:00 - Arm swelling is reduced, no body aches, minor fatigue, minor headache remains (no Tylenol) any attempt to use computer or phone resulted in minor headache going to full blown migraine
Flue like symptoms but only stronger; system completely blocked; Sweats; Took it's clothes off because it was cold and hot; Delusional because of the fever; Rash on the arm; Chills, Shivering; Fever of 40°C; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flue like symptoms but only stronger), UNEVALUABLE EVENT (system completely blocked), HYPERHIDROSIS (Sweats), FEELING OF BODY TEMPERATURE CHANGE (Took it's clothes off because it was cold and hot) and DELUSION (Delusional because of the fever) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038K20A and 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 in July 2020. Concurrent medical conditions included Hypertension.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flue like symptoms but only stronger), UNEVALUABLE EVENT (system completely blocked), HYPERHIDROSIS (Sweats), FEELING OF BODY TEMPERATURE CHANGE (Took it's clothes off because it was cold and hot), DELUSION (Delusional because of the fever), RASH (Rash on the arm), CHILLS (Chills, Shivering) and PYREXIA (Fever of 40°C). At the time of the report, INFLUENZA LIKE ILLNESS (Flue like symptoms but only stronger), UNEVALUABLE EVENT (system completely blocked), HYPERHIDROSIS (Sweats), FEELING OF BODY TEMPERATURE CHANGE (Took it's clothes off because it was cold and hot), DELUSION (Delusional because of the fever), RASH (Rash on the arm), CHILLS (Chills, Shivering) and PYREXIA (Fever of 40°C) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature increased: 40 degree Celsius (Inconclusive) 40°C.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient was doing ok at the time of report.  Products known to have been used by the patient, within two weeks prior to the event, included unspecified blood pressure pills. No treatment information was provided.   This case was linked to MOD-2021-049333 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 05-May-2021: Clinical course information.
11/8 2hr after injection-hives on arms-given antihistamine. 11/9 Hives increased to whole body-saw PCP-treated with OTC meds. 11/10 Hives and swelling of hands and feet-to ER-treated with IV steroids and oral steroids.
Development of bilateral lower extremity erythema. Per parent report, lower extremities also seemed to turn blue briefly. Returned to clinic from parking lot. By time of return, no cyanosis. Erythema of LE noted, no respiratory distress. Given BENADRYL.
Headache, chills,  body-ache, fever, nausea, vomiting, and weakness.
Pt recvd 3rd dose of Engerix B & was a non-responder; 4th dose was recvd on 25FEB91  & vax again was a non-responder;started 2nd series of vax.
Dark red, bumpy, itchy  rash about 2 inches in diameter at injection site. This first appeared around 7:00am on 3/5 2021.
23SEP98 devel fluid filled bumps on back of legs which progressed down back of neck to feet;some bumps had white centers, others turning purple;eyes swelling shut;T100;rash itching;hives;
This spontaneous report as received from a nurse practitioner refers to a 12 month old patient of unknown gender. No information on patient's medical history or concurrent conditions was provided. On 26-JAN-2015, the patient was vaccinated with the dose of PEDVAXHIB lot # K008874 (dose, strength, route of administration and expiration date were not reported) which had temperature excursion (incorrect product storage). No information on patient's concurrent concomitant medication was provided. No adverse events were experienced. This is one of several reports receive from the same reporter. Additional information has been requested.
Left shoulder began swelling and became sore, the day after injection. Went to ER on 7/11/01 and was given IV antibiotics. Swelling increased to 2 X natural shoulder size. Admitted to hospital on 7/13/01 and discharged on 7/14/01 with a dx of "infection" (cellulitis). They treated it with antibiotics. No further complications and has apparently fully recovered.
Tinnitus in my right ear. Started about two weeks after the vaccine booster and is still ongoing now two months later. I have been seen by an ENT and an audiologist who both confirm there is nothing wrong that is causing the tinnitus. My hearing is fine, no ear infections or fluid.
Sore first 3 days about quarter size.  Down to nickel size by day 4.  On day 7 started itching in the evening.  Morning of the 8th woke up with red, hot, stiff spot the size of a baseball.  Today April 11th,first day it is not hard and hot, but still red baseball size.
Fever, increased swelling that extended the entire upper arm elbow to shoulder. Extreme heat, swelling and itching
In October 2003, patient called me and told me that the site where her TD shot was had remained sore and over the past few months had become more severely painful especially upon rasing her arm and the she was having occasional tingling and numbness in her left hand.  Upon review by our missionary medical consultant, she consulted a neurologist who treated her with a Medrol dosepack and Celebrex.  Diagnosis myositis, bursitis as a reaction to the Td shot.  Recovery has been slow and was unable to return to work in December as scheduled.  Doctor told her it would take months to recover.
(L) thigh swollen from upper thigh to knee. 3 cm larger than (R) thigh. Area a little reddened. Afebrile.
This spontaneous report was received from a physician referring to unspecified number of patients. On an unknown date the patients were vaccinated with ZOSTAVAX, subcutaneous (strength and dose not reported). No other concomitant therapies reported. On an unknown date unspecified number of patients reported to the physician, receiving post herpetic neuralgia after receiving ZOSTAVAX. Physician does not request a VZVIP packet to be sent. No PQC reported. The outcome of post herpetic neuralgia was unknown. The causality of the events was unspecified. Additional information has been requested.
Possible administration of Havrix pediatric and MMR to a 7-month-old; This case was reported by a other health professional via sales rep and described the occurrence of inappropriate age at vaccine administration in a 7-month-old patient who received HAV (Havrix pediatric) for prophylaxis.   Co-suspect products included MMR (MMR vaccine) for prophylaxis.   On an unknown date, the patient received Havrix pediatric and MMR vaccine. On an unknown date, unknown after receiving Havrix pediatric and MMR vaccine, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK receipt date: 18-Nov-2022 Reporter's comment: The reporter reported that provider had a 7 month old patient.  Provider ordered MMR and Havrix Pediatric for patient. No further information shared other than what was noted in reporter's comments. Brand of MMR was not provided so unsure if Priorix or not. The reporter consented to follow-up. Additional supportive information: The patient received MMR Havrix Pediatric at inappropriate age, which led to inappropriate age at vaccine administration. The case was kept valid in worst approach considering that the patient had received both vaccine at age 7 month and for further clarification query was raised.
Heart palpitations; This is a spontaneous report from a contactable nurse (patient). A 38-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: 9810), via an unspecified route of administration, administered in the left arm on 25Feb2021 (at the age of 38 years old) as dose 2, single for COVID-19 immunization. Medical history included hypothyroidism, obesity, high cholesterol and cholecystectomy, all from an unknown date and unknown if ongoing. The patient is not pregnant. The patient's concomitant medications were not reported. The patient previously took ASA, erythromycin, Keflex, sertraline, ibuprofen and experienced allergies. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: 9264), via an unspecified route of administration, administered in the left arm on an unspecified date (pending clarification; at the age of 38 years old) as dose 1, single for COVID-19 immunization. The patient experienced heart palpitations on 20Mar2021. It was reported that the patient experienced heart palpitations starting in March and continues now to present date. No treatment was received. There was no other vaccine in four weeks. There was no COVID prior vaccination. The patient underwent lab tests and procedures which included Lumira Ag: negative (nasal swab) on 26Aug2021. The outcome of the event was not recovered.
This case was reported by a consumer via call center representative and described the occurrence of anaphylactic shock in a adolescent male patient who received dTpa vaccine. In 1993, the patient received dTpa vaccine .5 ml. In 1993, an unknown time after receiving dTpa vaccine, the patient experienced anaphylactic shock (serious criteria hospitalization and GSK medically significant). On an unknown date, the outcome of the anaphylactic shock was recovered/resolved. It was unknown if the reporter considered the anaphylactic shock to be related to dTpa vaccine. Addition details were provided as follow: The reporter was the patient's wife. The patient went into anaphylactic shock in 1993 after receiving an unknown Tdap vaccine (unknown manufacturer). The patient was hospitalized.
At time of vaccination, I was four weeks preganent. However, I started vaginal bleeding 7 days after the vaccination. The bleeding lasted two weeks. I lost my baby on Jan. 11th.
Patient received Immunization waited for 30 minutes no reaction on 10/25/17 returned to Pharmacy B/C arm hurt and had bruising referred Patient to MD.
Felt faint and had chills. No unconsciousness. Given water, BENADRYL syrup 2 tsp PO once, nasal O2. O2 sat and BP normal.
This case was reported by a other health professional via sales rep and described the occurrence of cellulitis in a adult female patient who received SHINGRIX (batch number 4G5HX, expiry date 9th July 2021) for prophylaxis. On an unknown date, the patient received SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced cellulitis (serious criteria GSK medically significant). On an unknown date, the outcome of the cellulitis was unknown. It was unknown if the reporter considered the cellulitis to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported, however the patient was in between the age of 50 and 60. The patient developed cellulitis after receiving SHINGRIX. The sales representative was unable to provide initials or ages for the patient. The sales representative could not provide the date the event occurred or the date of vaccination or if 1st or 2nd dose. This is 1 of the 2 cases reported by the same reporter. The batch number reported for INFANRIX (465HX) did not exist and was updated to 4G5HX, as per sales database.
Pt received 1st series of shots IPV, DTaP, Comvax. That evening, had fever, and was very cranky-then blisters to inferior with red for 2-3 days no swelling, tired looking per mom and  stuffy nose till now 03/16/2005
This spontaneous report as received from a healthcare worker refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 04-JUN-2014, the patient was vaccinated with the first dose of GARDASIL, intramuscularly, (dose, injection site, lot number and expiration date were not reported). According to the reporting healthcare worker, on 17-AUG-2015, the patient was receiving the second dose of GARDASIL, intramuscularly, (dose, injection site, lot number and expiration date were not reported). No adverse effects were reported. Additional information has been requested.
In April traveled by car to family ranch, where I experienced angio-edema reaction to my face and eyes. This is a family ranch to which I travel 2 to 6 times a year, but this past year this was the third time I experienced this facial reaction. The first time was in July, the second time was in November, and this was my third reaction. All three times I required steroids and was required to stay out of the sun. I experienced peeling of my skin, swelling, pain, and reddening of my skin. The only reason I wonder if there is a connection to the vaccines is that I have continually visited this ranch at various seasons without previously having had more than hayfever(these occurred in the summer, fall, and early spring)